Fukutomi T, Kubota T, Ikeda T, Isobe Y, Kikuyama S, Shimada A, Nakamura A, Nishiumi T, Enomoto K, Ishibiki K
Jpn J Cancer Res. 1986 Jan;77(1):92-7.
Experimental combined hormone therapy with tamoxifen, aminoglutethimide and medroxyprogesterone acetate was investigated using three hormone-dependent human breast carcinomas serially transplanted into nude mice. The antitumor effect of combined tamoxifen and aminoglutethimide was better than that of either tamoxifen or aminoglutethimide alone. Since aminoglutethimide significantly reduced the level of estrogen and the uterine weight in normal female mice, the antitumor effect of combined tamoxifen and aminoglutethimide was assumed to be a result of the low estrogen level produced by aminoglutethimide, favoring the competition of tamoxifen with estrogen receptors. There was no additive antitumor effect of the combination of tamoxifen and medroxyprogesterone acetate, although serum medroxyprogesterone acetate levels in nude mice were almost equivalent to those of humans. These results indicate that combination hormone therapy, especially with and aminoglutethimide, might be a promising method for clinical application.
使用三种激素依赖性人乳腺癌细胞系连续接种到裸鼠体内，对他莫昔芬、氨鲁米特和醋酸甲羟孕酮联合激素疗法进行了研究。他莫昔芬和氨鲁米特联合使用的抗肿瘤效果优于单独使用他莫昔芬或氨鲁米特。由于氨鲁米特能显著降低正常雌性小鼠的雌激素水平和子宫重量，因此推测他莫昔芬和氨鲁米特联合使用的抗肿瘤效果是氨鲁米特产生的低雌激素水平所致，有利于他莫昔芬与雌激素受体的竞争。他莫昔芬和醋酸甲羟孕酮联合使用没有相加的抗肿瘤效果，尽管裸鼠体内的血清醋酸甲羟孕酮水平几乎与人类相当。这些结果表明，联合激素疗法，尤其是与氨鲁米特联合，可能是一种有前景的临床应用方法。
